1. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, H.K. van Amstel, C.J. Lips, I. Nishisho, S.I. Takai, D.J. Marsh, B.G. Robinson, K. Frank-Raue, F. Raue, F. Xue, W.W. Noll, C. Romei, F. Pacini, M. Fink, B. Niederle, J. Zedenius, M. Nordenskjöld, P. Komminoth, G.N. Hendy, H. Gharib, S.N. Thibodeau, A. Lacroix, A. Frilling, B.A.J. Ponder, L.M. Mulligan, The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J. Am. Med. Assoc. 276, 1575–1579 (1996)
2. A. Machens, P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T.J. van Vroonhoven, H.D. Roeher, R.A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, H. Dralle, European Multiple Endocrine Neoplasia (EUROMEN) Study Group, Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 349, 1517–1525 (2003)
3. S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)
4. A. Machens, K. Lorenz, F. Weber, H. Dralle, Genotype-specific progression of hereditary medullary thyroid cancer. Hum. Mutat. 39, 860–869 (2018)
5. R. Elisei, V. Bottici, F. Luchetti, G. Di Coscio, C. Romei, L. Grasso, P. Miccoli, P. Iacconi, F. Basolo, A. Pinchera, F. Pacini, Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab. 89, 163–168 (2004)